By:
On:
In: Actions

The David Geffen School of Medicine at UCLA has responded on behalf of the University of California to UACT’s recent letters on the Xtandi (INN:enzalutamide) patent in India. In a letter sent by post dated September 7, 2017, received on September 19, 2017, (copy  here)Dr. John C. Mazziotta, the Vice Chancellor for UCLA Health Sciences and the CEO of the UCLA Health System wrote to UACT, rejecting the request by UACT and others that the University abandon its appeal of a rejection of enzalutamide patent in India. Mazziotta did say “UC has brought to Medivation’s attention the concerns UACT has raised, ” but that wasRead More →